Alloy Therapeutics is a biotech ecosystem company, facilitating affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. The company's platform is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/03/2022 | Series D | $41.74MM | $xx.xx | $73.62B | 8vc, Founders Fund, Mubadala Capital, Presight Capital, Thiel Capital | |
Price per Share
$xx.xx
Shares Outstanding
1,973,698
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Founders Fund, Mubadala Capital, Presight Capital, Thiel Capital
|
||||||
04/02/2021 | Series C | $75MM | $xx.xx | $56.3B | 8vc, Alexandria Venture Investments, Founders Fund, Gaingels, Luma Bio-It, Mubadala Capital, Peter Thiel, Presight Capital, Ulysses Diversified Holdings | |
Price per Share
$xx.xx
Shares Outstanding
4,462,950
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Alexandria Venture Investments, Founders Fund, Gaingels, Luma Bio-It, Mubadala Capital, Peter Thiel, Presight Capital, Ulysses Diversified Holdings
|
||||||
05/31/2020 | Series B | $11.25MM | $xx.xx | $9.13B | Alexandria Venture Investments, Luma Bio-It, Ulysses Diversified Holdings | |
Price per Share
$xx.xx
Shares Outstanding
3,205,219
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Luma Bio-It, Ulysses Diversified Holdings
|
||||||
04/13/2020 | Series A-1 | $500,042.00 | $xx.xx | $3.73B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,444,374
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
04/13/2020 | Series A-2 | $1.5MM | $xx.xx | $3.73B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,949,906
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
04/13/2020 | Series A-3 | $6.25MM | $xx.xx | $3.73B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,290,235
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|